In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Mona El-Bahrawyto discuss ovarian sex cord stromal tumors. Dr. El-Bahrawy is the lead author of “Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management" (https://ijgc.bmj.com/content/early/2021/01/07/ijgc-2020-002018), which is the Lead Article of IJGC’s February 2021 issue.

Dr. El-Bahrawy is Professor of Practice in Histopathology at Imperial College London, United Kingdom, and Professor of Pathology at the University of Alexandria, Egypt, and President of the Egyptian Committee for Pathology Training. She specializes in Gynaecological Surgical Pathology with special interest in Gynaecological Tumour Pathology.

Highlights:
- Ovarian sex cord stromal tumours are rare tumours that include benign and malignant variants.
- They are broadly classified into three categories, which include pure stromal tumors, pure sex cord tumors and mixed sex cord stromal tumors.
- Some tumor types harbor hallmark mutations, such as FOXL-2 mutations detected in the majority of adult granulosa cell tumors.
- Surgery is the main treatment modality for sex cord stromal tumors with some role for chemotherapy and hormonal therapy in advanced and recurrent tumors.
- There is potential for the identification of therapeutic targets and development of targeted therapy for these tumors.